Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
An Iran Red Crescent official said the helicopters are fitted with firefighting equipment and can provide medical and rescue services.
2026-06-17
An Iran Red Crescent official said the helicopters are fitted with firefighting equipment and can provide medical and rescue services.
Back
Other News
2026-06-17
Changshan Pharmaceutical shares fell 15.15% to 24.92 yuan at close on June 17. A China weight-loss drug index dropped 1.82%. The move followed a report that Changshan’s GLP-1 obesity candidate Aibennatide, having just completed a prior round of suppl
Changshan Pharmaceutical shares fell 15.15% to 24.92 yuan at close on June 17. A China weight-loss drug index dropped 1.82%. The move followed a report that Changshan’s GLP-1 obesity candidate Aibennatide, having just completed a prior round of supplementary submissions, received a second-round supplementary-data notice from the CDE, cooling near-term expectations. Changshan said it is not accepting media interviews. Several listed weight-loss companies said Aibennatide is Changshan’s independently developed single-target GLP-1; competition is most intense among single-target products such as semaglutide and liraglutide, while many firms are developing dual- and triple-target GLP-1s. Firms added a delay to Aibennatide would primarily affect Changshan, not peer concept stocks; an unnamed executive said single-target generics are expected around 2027 and are unrelated to Changshan’s approval timeline.
2026-06-18
Federal Reserve Chairman Warsh: (When asked if he had spoken with Trump) There's nothing I can tell you.
Federal Reserve Chairman Warsh: (When asked if he had spoken with Trump) There's nothing I can tell you.
Chat with us
, powered by
LiveChat